Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO PracticeUpdate Conference Series:

Videos from #ESMO20 on Thoracic Malignancies

Key Takeaways from ESMO: Adjuvant and Neoadjuvant Therapy for NSCLC

Jean-Yves Douillard

  1. What did we learn about targeted therapy and adjuvant therapy for lung cancer at this conference?
  2. What did the updated results from ADAURA presented at ESMO focus on?
  3. Are there any other data on targeted agents in the adjuvant setting for NSCLC that you’d like to highlight?
  4. What about the neoadjuvant setting using immunotherapy?
  5. Were there any data on radiation therapy in the adjuvant setting for NSCLC presented at ESMO?
Key Takeaways from ESMO: Updates on Small-Cell Lung Cancer

Jean-Yves Douillard

  1. What are the most impactful studies at this year’s ESMO pertaining to the use of immunotherapy in small-cell lung cancer?
  2. How is the high-dose twice-daily dose of radiation tolerated in patients with small-cell lung cancer?
  3. What other trials at this year’s ESMO were practice-informing in small cell lung cancer?
  4. How do the updated results of the CASPIAN trial, also presented at ESMO, add to these?
  5. Was there quality of life data presented on the addition of immunotherapy to conventional platinum-based chemotherapy in extensive small-cell lung cancer?

The ESMO PU Conference Series – A collaboration brought to you by Elsevier’s PracticeUpdate and the European Society for Medical Oncology.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings